Samaglutide is a new type of GLP-1 analogue that is injected subcutaneously once a week. Samaglutide is a long-acting GLP-1 analogue developed by Novo Nordisk that is injected subcutaneously once/w. alsohas a longer fat chemical chain and increased hydrophobicity, but samaglutide is modified with short-chain PEG, which greatly enhances its hydrophilicity. After PEG modification, it can not only bind tightly to albumin and mask the DPP-4 enzyme hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve a long circulation effect.